Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 4/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | CFTR | P13569 | 3/20 | 0.37 |
| ▸ | IKBKB | O14920 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30467766 | 0.91 | CFTR (0.40) | NOTUMPRKCZRAB9AKDM4EALDH1A1 | |
| SCHEMBL517686 | 0.87 | NOTUM (0.47) | NOTUMPRKCZRAB9AKDM4EALDH1A1 | |
| SCHEMBL3274931 | 0.82 | KDM4E (0.43) | RAB9AKDM4EALDH1A1MAPTHPGD | |
| SCHEMBL3860214 | 0.82 | RAB9A (0.44) | NOTUMPRKCZRAB9AKDM4EALDH1A1 | |
| SCHEMBL24745625 | 0.81 | KDM4E (0.47) | NOTUMPRKCZRAB9AKDM4EALDH1A1 | |
| SCHEMBL1041318 | 0.81 | CYP3A4 (0.47) | NOTUMKDM4EALDH1A1MAPTHPGD | |
| SCHEMBL20076067 | 0.81 | NOTUM (0.42) | NOTUMKDM4EALDH1A1MAPTGAA | |
| SCHEMBL29429473 | 0.81 | CYP3A4 (0.47) | NOTUMKDM4EALDH1A1MAPTHPGD | |
| SCHEMBL17419113 | 0.81 | CYP3A4 (0.47) | NOTUMKDM4EALDH1A1MAPTHPGD | |
| SCHEMBL17963734 | 0.81 | CYP3A4 (0.47) | NOTUMPRKCZRAB9AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098024-A1 | PARP1 INHIBITORS AND USES THEREOF | XINTHERA INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250332173-A1 | COMPOUNDS AND METHODS FOR MODULATING NUCLEIC ACID SPLICING | REMIX THERAPEUTICS INC (US) | 2025-10-30 | — | — | US | disclosed |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| EP-4565574-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2025-06-11 | — | — | EP | disclosed |
| US-20250163022-A1 | PARP1 INHIBITORS | SYNNOVATION THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-12234244-B2 | Substituted piperazines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2025-02-25 | — | — | US | disclosed |
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2025-02-06 | — | — | US | disclosed |
| CN-119278199-A | Kinesin KIF18A inhibitor and application thereof | 上海湃隆生物科技有限公司 | 2025-01-07 | — | — | CN | disclosed |
| US-9840516-B2 | Substituted quinazolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2017-12-12 | — | — | US | disclosed |
| US-9840516-B2 | Substituted quinazolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2017-12-12 | — | — | US | disclosed |
| US-9840516-B2 | Substituted quinazolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2017-12-12 | — | — | US | disclosed |
| WO-2017098440-A1 | SUBSTITUTED BENZAZINONES AS ANTIBACTERIAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-06-15 | — | — | WO | disclosed |
| EP-3055290-A1 | INHIBITORS OF KRAS G12C | Araxes Pharma LLC (US) | 2016-08-17 | — | — | EP | disclosed |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2015-08-27 | — | — | US | disclosed |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2015-08-27 | — | — | US | disclosed |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2015-08-27 | — | — | US | disclosed |
| WO-2015054572-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2015-04-16 | — | — | WO | disclosed |
| WO-2015054572-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | NOTUM 188/4885PRKCZ 3402/4885RAB9A 2168/4885 |
| US-20250332173-A1 | COMPOUNDS AND METHODS FOR MODULATING NUCLEIC ACID SPLICING | SNRPA, NSUN2, SNRPA1 | NOTUM 4089/4885PRKCZ 1694/4885RAB9A 3301/4885 |
| US-12234244-B2 | Substituted piperazines as inhibitors of KRAS G12C | KRAS, NRAS, HRAS | NOTUM 4804/4885PRKCZ 419/4885RAB9A 17/4885 |
| US-20250163022-A1 | PARP1 INHIBITORS | PARP1, PARP11, PARP12 | NOTUM 4382/4885PRKCZ 468/4885RAB9A 2325/4885 |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | ACE2, TMPRSS2, ACE | NOTUM 188/4885PRKCZ 3402/4885RAB9A 2168/4885 |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | SSB, UACA, CFH | NOTUM 3713/4885PRKCZ 735/4885RAB9A 2629/4885 |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | NOTUM 4808/4885PRKCZ 861/4885RAB9A 33/4885 |
| US-20260098024-A1 | PARP1 INHIBITORS AND USES THEREOF | PARP1, PARP11, PARP16 | NOTUM 2357/4885PRKCZ 409/4885RAB9A 3169/4885 |
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFH, CFB, C5 | NOTUM 1663/4885PRKCZ 1093/4885RAB9A 1991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.